DDInter915 DDInter1032
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August 2019. This drug is the first semi-synthetic pleuromutilin that has been designed for systemic administration. Lefamulin features a novel mechanism of action that shows benefit against resistant bacteria that cause pneumonia. The chemical structure of lefamulin contains a tricyclic mutilin core that is necessary for some of its antimicrobial activity.
Indacaterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Indacaterol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Formoterol
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Indacaterol {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Indacaterol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lefamulin
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Indacaterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is upregulated by {v} (Compound) Teniposide
Teniposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Indacaterol {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lefamulin
Indacaterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Dry mouth {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lefamulin
Indacaterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Orciprenaline
Orciprenaline {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Indacaterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Indacaterol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Formoterol (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Indacaterol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Lefamulin
Indacaterol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Indacaterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Teniposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Lefamulin
Indacaterol (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Indacaterol (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Indacaterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Orciprenaline (Compound) and Orciprenaline may lead to a major life threatening interaction when taken with Lefamulin